More than 200 Cases Join Federal Lipitor Lawsuit Litigation in a Month

Published on March 17, 2014 by Sandy Liebhard

Text-Size:A A A+

 

Lipitor lawsuit claims are steadily increasing in a federal litigation underway in South Carolina, where more than 270 cases have now been filed over the cholesterol-lowering statin.

A Case List updated March 13th by the U.S. Judicial Panel on Multidistrict Litigation (JPML) shows a new total of lawsuits that accuse Pfizer Inc. of failing to warn about the risk for its product to cause new-onset diabetes and other side effects. When the proceeding was created last month in the U.S. District Court, District of South Carolina, just 56 Lipitor diabetes lawsuits were transferred from various U.S. jurisdictions.

Plaintiffs in these cases argue that warnings provided by Pfizer are insufficient, even after the company was ordered by the U.S. Food and Drug Administration (FDA) to update its labeling in February 2012. This FDA mandate followed the findings of a January study published in JAMA: Internal Medicine that revealed post-menopausal women treated with Lipitor were at an increased risk for Type 2 diabetes diagnoses. Among other things, plaintiffs go on to say that Pfizer was negligent and reckless in designing, manufacturing and marketing the cholesterol drug.

ACC Files Federal Lipitor Lawsuit in Sidney

Rising product liability lawsuit litigation is not the only legal battle Pfizer must prepare to face, according to court documents. On February 13th, the Australian Competition and Consumer Commission (ACC) filed a complaint in Sydney federal court that accuses the company of attempting to curtail generic drug competition through significant rebate and discount offers in exchange for a year-supply of Lipitor. A Reuters report from that day indicates that Pfizer engaged in these practices after the medication lost patent protection in 2012.

As Lipitor litigation continues to mount, the Wall Street Journal recently reported on Pfizer’s progress in conducting clinical trials for an over-the-counter version of the drug. Releasing an OTC version of the drug will hopefully reclaim some of the market share that was lost when Lipitor lost patient protection in 2011, according to the article, which also states that the purpose of the trials is to determine whether patients will be able to properly monitor themselves for side effects.

Lipitor entered the market in 1996 and is approved to treat high cholesterol.

Filing a Lipitor Lawsuit

If you were diagnosed with Type 2 diabetes after taking Lipitor, you may be eligible to file a claim against Pfizer. Call our Firm to receive a free and confidential case evaluation at (888) 723-0074.